Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
Name:
Diamond et al_final.pdf
Size:
1.820Mb
Format:
PDF
Description:
allowed publisher's PDF
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Diamond, Mark SKinder, Michelle
Matsushita, Hirokazu
Mashayekhi, Mona
Dunn, Gavin P
Archambault, Jessica M
Lee, Hsiaoju
Arthur, Cora D
White, J Michael
Kalinke, Ulrich
Murphy, Kenneth M
Schreiber, Robert D
Issue Date
2011-09-26
Metadata
Show full item recordAbstract
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shapes tumor immunogenicity. We previously reported that type I interferon (IFN-α/β) plays a central role in this process and that hematopoietic cells represent critical targets of type I IFN's actions. However, the specific cells affected by IFN-α/β and the functional processes that type I IFN induces remain undefined. Herein, we show that type I IFN is required to initiate the antitumor response and that its actions are temporally distinct from IFN-γ during cancer immunoediting. Using mixed bone marrow chimeric mice, we demonstrate that type I IFN sensitivity selectively within the innate immune compartment is essential for tumor-specific T cell priming and tumor elimination. We further show that mice lacking IFNAR1 (IFN-α/β receptor 1) in dendritic cells (DCs; Itgax-Cre(+)Ifnar1(f/f) mice) cannot reject highly immunogenic tumor cells and that CD8α(+) DCs from these mice display defects in antigen cross-presentation to CD8(+) T cells. In contrast, mice depleted of NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these tumors normally. Thus, DCs and specifically CD8α(+) DCs are functionally relevant targets of endogenous type I IFN during lymphocyte-mediated tumor rejection.Citation
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. 2011, 208 (10):1989-2003 J. Exp. Med.Affiliation
Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.PubMed ID
21930769Type
ArticleLanguage
enISSN
1540-9538ae974a485f413a2113503eed53cd6c53
10.1084/jem.20101158
Scopus Count
The following license files are associated with this item:
Related articles
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.
- Authors: Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM
- Issue date: 2009 Jul 6
- Type I IFN Sensing by cDCs and CD4(+) T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8(+) T Cells.
- Authors: Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, Morel LM, Wallet MA, Terhorst C, Herzog RW
- Issue date: 2020 Mar 4
- Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.
- Authors: Kamath AT, Sheasby CE, Tough DF
- Issue date: 2005 Jan 15
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
- Authors: Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF
- Issue date: 2011 Sep 26
- Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
- Authors: Lu C, Klement JD, Ibrahim ML, Xiao W, Redd PS, Nayak-Kapoor A, Zhou G, Liu K
- Issue date: 2019 Jun 22